Search
+
    SEARCHED FOR:

    BS AJAIKUMAR

    HCG uses AI, patient data to personalise cancer treatment: BS Ajaikumar, founder

    Healthcare Global Enterprises is using artificial intelligence and patient data. Algorithms are being developed to personalise cancer treatment and improve outcomes. The company analyses clinical and genomic data to classify patients for better decisions. HCG partnered with Accenture to enhance its AI research capabilities.

    KKR to buy cancer care hospital chain HCG from CVC for $400 million

    KKR acquires a controlling stake in Healthcare Global from CVC Capital Partners for Rs 3466 crore, strengthening its presence in the healthcare sector. The deal gives KKR up to 77% ownership, and Dr. BS Ajaikumar will take on a new role as Non-Executive Chairman.

    KKR set to buy cancer chain HCG

    KKR is set to acquire a 51% stake in Healthcare Global Enterprises from CVC Capital Partners. The $3,128 crore deal includes an open offer for an additional 26%. HCG's founding family will retain 10.87%, while the company's growth trajectory and expanded capabilities are expected post-acquisition.

    KKR close to buying cancer chain HCG

    KKR is close to acquiring a 60.36% stake in Healthcare Global Enterprises Ltd (HCG), trumping Bain Capital's bid. The acquisition from CVC Capital is worth ₹4,663.12 crore. The deal includes a potential open offer for an additional 26% of HCG, possibly leading to the delisting of the hospital chain.

    HCG founder floats $20 million healthcare and life sciences fund

    BS Ajaikumar launched the $20 million Inviga Healthcare Fund to support Indian early-stage healthcare companies, addressing funding and operational challenges. The fund recently invested $2 million in Mynvax for novel vaccines.

    Dr BS Ajaikumar on CVC selling Healthcare Global controlling stake, future plans and more

    Dr BS Ajaikumar, Executive Chairman of Healthcare Global, is focused on achieving margin and expects growth. HCG plans to do more M&As and is looking for a long-term partner. There is potential for significant growth in oncology, driven by increased private insurance and expansion into tier II and III cities.

    The Economic Times
    BACK TO TOP
    Advertisement